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 4 
Summary 
 
This PhD project is focussed on the application of different strategies to develop new 
molecules able to interact with potential pharmacological targets. In particular, different 
approaches have been undertaken for the identification and optimization of hit and lead 
molecules. Computer-aided methodologies and computational tools, such as Molecular 
Mechanics and Quantum Mechanics, have been applied to better understand the chemical-
physical features of the resulting protein-ligand adducts. Sample target proteins have been 
selected on the basis of their involvement in human diseases; more precisely, ligands have 
been designed to interact with these biomolecules, in such a way as to provide a therapeutic 
activity by interfering with the proteins function and related pathways. These ligands 
belong either to the broad class of enzyme inhibitors and to the less numerous class of the 
inhibitors of protein-protein interaction, according to the target protein’s biological 
features. This computational investigation, flanked and supported by experimental data, 
highlights both the potentialities and the weakness of in silico approaches to drug design 
and discovery. 
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1. Introduction to drug design 
 
The main therapeutic approach to human diseases is historically represented by the 
administration of synthetic and natural drugs. In the last decades, the need to increase the 
drugs’ efficacy and to reduce their side effects resulted in the prevalent use of synthetic, ad 
hoc designed, molecules. 1 The fast-growing knowledge on biological systems has 
permitted a more efficient approach for designing ligands aimed at interacting with specific 
target macromolecules or metabolic and signalling pathways. Moreover, the complete 
sequencing of the human genome, 2,3 successfully carried out less than a decade ago, has 
provided great improvements in the field of life-sciences, and particularly in 
biotechnological research; the functional association between a gene and its related protein 
and pathways is a key point for approaching new strategies in drug discovery. 2,4 In the so 
called post-genomic era, efforts are now focused to understand the role of proteins in 
biological pathways and human diseases notably to derive new ligand compounds as 
therapeutics agents. A key component of these efforts is the use of protein structures in 
experimental design of drugs. 5 One of the major challenges is to translate all of the 
structural data into pharmaceutical knowledge, in particular to improve the pertinence and 
the specificity of the targets using genome-based drug discovery strategies. To achieve 
these objectives, many different methodologies have been developed, based on the use of 
protein structure data banks, combined with molecular modelling and exploitation of the 
energetic aspects of binding. 6,7 
Drug Design (DD) is the approach used to find drugs aimed at interacting with biological 
targets. It is currently one of the most reliable approaches for the identification of ligands 
with a certain biological activity; it can be considered as the logic evolution of the gene 
sequencing, technological progress, and the continuous need of, and search for innovative 
molecules to introduce in therapy. For these reasons, drug design approaches are nowadays 
widely undertaken in drug discovery by applying a large diversity of techniques and 
methodologies that span from chemistry to biology, and from in vitro experiments to in 
silico predictions of molecular properties. 5 Two main approaches common to all these 
strategies can be identified: Ligand-Based (LBDD) and Structure-Based (SBDD) Drug 
Design. The joint implementation of these two methods led to the Structure and Ligand-
Based Drug Design (SLBDD). These names are rather self-explanatory. A fourth approach, 
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based on theoretical models for not yet structurally defined biological targets, has to be 
mentioned. 8 In the frame of each approach, a “rational” 9 or “irrational” strategy can be 
undertaken during the ligand selection process. Rational drug design is aimed at tailoring 
molecules beginning from the knowledge of some structural data and/or chemical response 
on the target organism, whereas with the term “irrational” are intended all that procedures 
that are generally free of structural foundations on ligand or target receptors. Indeed the 
irrational approach does not address any relationship between ligand’s chemical structure 
and biological evidences, with respect to the rational drug design in which the so called 
Structure Activity Relationships (SAR) constitute a powerful guideline for the design of 
new molecules. These two philosophies can be also sequentially applied during the 
development of a large scale drug design project.  
 
1.1. Ligand-Based Drug Design. Despite the great technological improvement in the field 
of protein spectroscopy and characterization, the 3D structure of about 75% of the 
validated target proteins has not yet been determined or made available. 8 However, many 
specific ligands are well known and described to bind these particular receptors, ranging 
from agonists to allosteric activators/inhibitors across antagonists and competitors. The 
ligand-based approach is aimed at extracting numerical properties for describing physical, 
chemical, and biological behaviours of the selected molecules towards that target proteins 
whose structure is not known, and for which is not possible to apply the structure-based 
approach. In particular, all those directly or indirectly measurable properties are defined as 
molecular descriptors. The pattern analysis between the variability of experimental 
observations and the correspondent molecular descriptor sets the bases to obtain 
Quantitative Structure Activity Relationships (QSAR) 10 that, by providing a 3D and 
physical description of the ligand’s pharmacophores, can be exploited for designing new 
ligands. Due to the lack of the structure of target proteins, this approach is exclusively 
based on the chemical and biological properties of known and new ligands, and its 
reliability is proportional to the number of used molecules to asses the QSAR.  
 
1.2. Structure-Based Drug Design. Technological progress in the fields of protein 
expression and spectroscopic characterization have made available a large and 
continuously growing number of 3D proteins structures. For target proteins whose structure 
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is available, the drug design approach is carried out by tailoring ligands on the basis of the 
spatial conformation of the target. 5,7 With respect to the ligand-based approach, the atomic 
detail of the intermolecular interaction constitute the driving force to optimize the binding 
properties of ligands. SBDD highlights the differences between rational and irrational 
approaches. Just as example, when the binding site of the target protein is defined, a 
rational approach can be undertaken in order to select and develop molecules that interact 
only in that specific protein region. When the binding site is not defined, an irrational 
approach can be planned to explore the protein region mainly involved in ligand binding. 
The logical joint implementation or these two approaches is represented by the time 
sequence of irrational and rational methods.  
 
1.3. Structure and Ligand-Based Drug Design. Many target proteins are characterized in 
their ligand and/or substrate binding conformation. Thus, the knowledge of the chemical 
structure and binding pose for some specific ligands can be exploited for the design of new, 
“further-generation” of molecules. 11 Moreover, the knowledge of the binding 
conformation of the target protein generally provides higher reliability in ligand design. 
This is mainly a rational approach, and the availability of a starting compound constitutes a 
great advantage in drug design. 
 
1.4. Model-Based approach. An undefined number of potential target proteins are still 
uncharacterized. In case no ligands have been tested or described towards these proteins, 
and in vitro assays are unavailable for testing their biological response to ligand binding, 
the above described approaches cannot be undertaken. For this completely irrational 
approach, the most common procedure requires the computer-aided building of a homology 
model of the biological target on which to test, by virtual simulations, a set of ligands. The 
reliability of these models is proportional to the sequence homology between the target 
protein and the reference structure. It has been estimated that the structure of about 20% of 
validated target proteins, still  not characterized, could be modelled on the basis of the 
structure of highly homologous proteins available on protein databases. 8 This model-based 
approach is more frequently carried out for tailoring ligands towards membrane proteins, 
ion channels and new, unstructured, target proteins. 12,13 However, it is not always feasible 
because many potential drug targets, inside the cell, are constituted by oligomers of protein 
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and receptors, whose complex structures are quite difficult to be modelled with these 
bioinformatics approaches right now available.  
 
 
 
Figure 1. Schematic representation of the dependence between the described approach 
(right column) and the availability of the starting molecules. 
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2. Computer Aided Drug Design 
 
The above described approaches are schematized in Figure 1. Despite the different 
methodologies that can be undertaken during each approach, the aim of drug design is to 
discover lead molecules to be developed and optimized as candidate drugs. It has to be 
considered that the probability of success for a general lead discovery project is 
proportional to the number of starting molecules. The PubChem Database, as example, is 
one of the most complete database of existing organic molecules and comprises about 19 
million of compounds and 41 million of substances, 14 whereas the ZINC database 15 
contains over 8 million purchasable molecular hits. As they appear, these databases 
represent an excessive amount of molecules to be managed during a drug discovery project. 
Drug design is thus aimed at drastically reducing the number of putative ligands for each 
target, down to a reasonable and handy number of leads, by filtering the initial large set of 
molecules by specific filters chosen on the basis of the selected methodology. A filter can 
be represented in a first instance by the experimentally measured, or in silico predicted, 
biological activity; many other filters can be added, such as toxicity evaluation or 
prediction, analysis of the synthetic perspectives, molecular weight or other chemical 
features related to the Lipinski’s rules (see chapter 5.2).  
The huge amount of starting molecules that can be putatively considered in drug design, 
however, represents a limiting factor for the time duration of the entire process, especially 
when approached by sophisticated techniques as X-Ray crystallography and NMR 
spectroscopy. To get around the problem, in the last decades computer aided procedures 
have been developed. In this way, the initial phases of each approach are supplied by in 
silico simulations of the ligands and/or of protein-ligand adducts behaviour, focussing the 
experimental efforts only to the most promising ligands. 
The development of focussed software has greatly contributed to the widespread usage of 
computer aided drug design. 16-18 This method makes use of computational chemistry to 
simulate the molecular behaviour of both ligands and macromolecular target, in order to 
discover and optimize new candidate drugs aimed at interacting with biologically active 
macromolecule such as proteins or DNA polymers. This in silico methodology includes 
simple molecular modelling, using molecular mechanics, molecular dynamics, semi-
empirical methods and ab initio quantum chemistry to select the most promising hits and 
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leads on which to concentrate the time-consuming experimental procedures. By the way, 
hits are defined as promising ligands, generally characterized by a molecular weight lower 
than 300 daltons, that provide a certain activity in preliminary tests, whereas with the term 
leads are considered all the molecules with a molecular weight generally within the range 
300-500 daltons, optimized towards the selected target according to the pharmacological 
criteria of efficacy, safety and ADME properties (Absorption, Distribution, Metabolism, 
Elimination). Moreover, hits and leads follow the Lipinski’s “rule of 3” and “rule of 5” 
respectively, as further discussed.  
Computer aided drug design needs to be complemented by experimental data, especially in 
developing new methods and to provide confirmations about the reliability of  the selected 
approach.  
 
This in silico methodology has been selected to carry out the project described in this 
thesis. Molecular modelling procedures were investigated, as further described, with the 
aim to identify hit or lead compounds towards the selected target proteins. More precisely, 
docking calculations were performed during the preliminary ligands screening steps, 
whereas molecular dynamics and quantum mechanics were applied for the refinement and 
optimization of the docking results. During this project both synthetic molecules and 
peptides were accounted as candidate drugs. 
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3. Computational methods 
 
This PhD project is mainly focussed on in silico drug design. In particular, due to the 
availability of the 3D structure of the selected target proteins, the structure based approach 
has been carried out in both rational and irrational ways to design ligands. Computational 
techniques and theoretical methods were applied to model the molecular behaviour of 
ligands, targets and their resulting complexes and adducts.18 Here is reported a brief and 
basic description of the computational methods used in this work. The techniques listed 
below were exploited in a case-specific manner, on the basis of the level of refinement 
requested for the results.  
 
3.1. Molecular Mechanics (MM) and Docking. Under the name “molecular mechanics” are 
collected all the simulations that refer to the use of Newton’s mechanics equations to 
approximate molecular properties and behaviour. Accordingly, atoms are considered as 
solid spheres with mass proportional to their atomic weight and a radius corresponding, in 
general, to the Van-der-Waals atomic radius. Electrons are not accounted for; hence, atom 
charges and polarization properties cannot be computed during MM calculations and have 
to be retrieved from quantum chemistry or experimental data, where available. Bonded 
interactions are treated as springs, with strengths and distances assigned from available 
experimental or quantum chemistry data. The functional application of molecular 
mechanics is the force field equation that describes all the terms involved in the energy 
calculation. 19,20 In a generic force field, bonds, bond angles and dihedral angles are 
considered as harmonic potentials centred around the equilibrium values, that are 
experimentally calculated or theorized by ab initio computations. The implementation of 
force field equations by the addition of non-bonding terms (VdW, electrostatic and 
solvation/desolvation) completes the chemical and physical description of the molecular 
environment. These equations are generally applied in the energy minimization process of a 
single molecule. However, force fields can even be used for the energy minimization of a 
complex of molecules such as ligand-protein adducts; one of the methods for exploring this 
aspect of binding is docking. Docking is the easiest process by which two molecules fit 
together in 3D space. It is a MM-based approach to molecular modelling commonly 
applied for the prediction of binding conformations, and relative energies, of molecules 
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towards a target receptor. The docking methodology can be approached for the prediction 
of protein-protein conformation and energy of interaction (protein docking), or to simulate 
the interaction between a protein and a ligand (molecular docking). Molecular docking has 
been largely used in the present work; it represents the first and most intuitive tool for the 
in silico structure-based drug design, allowing the prediction of preferred orientations, and 
their relative binding energies, of small molecules towards target proteins.  
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Equation 1 – AutoDock force field equation for the calculation of the Free Energy of 
Binding 
 
In equation 1 is described the general formula for the calculation of the free energy of 
binding, in the way it is used by AutoDock program. 21-23 This energy is considered as the 
sum of different contributions that are determined by linear regression analysis of 
complexes with known 3D-structures and known binding free energies. More precisely, 
these free energy weights are: Van-der-Waals energy (calculated by the 12-6 Lennard-
Jones equation, solved for each pair of i and j atoms), hydrogen bond energy (considered as 
a 12-10 Lennard-Jones potential plus an energetic adjustment related to the angle between 
acceptor and donor), electrostatic energy (calculated by the Coulomb’s equation 
implemented with the dielectric constant), ligand’s torsional energy and solvation energy 
(parameterized as the contribution of the full complexes minus the only protein solvation 
energy). In Lennard-Jones equations for non-bonding contribution to the total energy of the 
system, coefficients A, B, C and D, reported in equation 1, correspond to 4εσn where ε is 
the depth of the potential well and σ is the (finite) distance at which the interparticle 
potential is zero. The n exponent refers to the order of the specific term. Just as example, 
the Van-der-Walas coefficients A and B for carbon-carbon interaction are 373712.5 and 
182.5, whereas the same coefficients for oxygen-carbon interaction are 121872.1 and 
112.0, respectively. 
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According to the standard operating mode of AutoDock 3.0.5, the structure of the target 
protein is kept unchanged during the simulation of the ligands’ pose. In this way, rigid 
docking corresponds to the early pharmaceutical concept of “lock-and-key” for ligand-
protein interactions, where the protein can be thought of as the “lock” and the ligand can be 
thought of as a “key”. The docking procedure considers the target receptor as a rigid body 
on which to bind the flexible ligand. This mechanism, however, introduces an 
approximation relative to the protein-ligand reciprocal adaptation that occurs in a 
physiological environment. The lock-and-key concept has been progressively dismissed in 
favor of the “hand-and-glove” or “induced-fit” mechanism for which both protein and 
ligand modify their conformation due to a reciprocal adaptation. With the aim to increase 
the reliability of Docking simulations, this problem can be circumvented, for example, by 
taking a particular care in the choice of the target protein’s conformation. Interestingly, this 
approximation on the protein behaviour determines a faster solution of equation 1 in which 
the atoms i and j involved in intra-protein interactions are not accounted for. 
Programs for flexible docking have been also developed to permit the movements of small 
residues’ side chains, in order to moderately adapt the protein conformation to the ligand 
binding. Backbone atoms and side chains of bulky residues such as phenylalanine, tyrosine 
and arginine, are kept fixed as in the rigid docking protocol; these residues, however, 
greatly participate to the ligand interaction and stabilization introducing a limit to this 
methodology. Moreover, the partial flexibility of the protein determines a higher number of 
atoms to be computed in the force field equation, resulting in increased time of calculation, 
and attributing to flexible docking a limited applicability. Nevertheless, rigid docking 
represents a powerful tool for the hit selection and lead optimization processes, especially 
thanks to some of its advantages, such as the speed of calculation, the graphical rendering 
of the results and the reliability. For these reason docking procedures are largely applied for 
virtual screening. 
In the present PhD project docking procedures were applied for the irrational virtual 
screening of libraries and for rational drug design towards the selected target proteins, with 
the aim to provide preliminary information about the molecular scaffolds suitable for 
optimization and their relative energy of binding. 
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3.2. Molecular Dynamics (MD). One of the possible approaches to refine and optimize 
docking results is represented by Molecular Dynamics. MD is again a molecular mechanics 
technique but, with respect to docking, can take into account the reciprocal movements and 
the time evolution of protein-ligand or protein-protein complexes. Indeed, with this method 
the movements of the target receptor can be accounted during the reciprocal adaptation and 
arrangements of its complex with a ligand; for this reason Molecular Dynamics represents 
the most reliable tool to switch from the “lock-and-key” like approximation observed with 
rigid docking simulations, to a “induced-fit” like simulation of the interaction. In a general 
view, the MD process consists in supplying a stressing amount of energy to the system with 
the purpose to analyze the conformational variation during the recovering at the energetic 
state of minimum. So, even MD is a procedure for energy minimization and, such as 
docking, energy is calculated by an equation that describe the relative force field (equation 
2, Basic Amber Force Field).  
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Equation 2 – Amber force field for the potential energy calculation. The energy of a system 
is calculated as the sum of bond, angles, dihedrals, Van-der-Waals and electrostatic 
contributions. Weights and coefficients are calculated in the same way as above described 
for AutoDock. 
 
During the present project the Amber package 24-26 (versions 8, 9 and 10) was used in order 
to refine the conformation of the most interesting ligand-protein complexes, as obtained 
from preliminary docking simulations. The reciprocal conformation of target protein and 
ligand at the energy convergence, together with other energetic and geometric variables, 
was taken into account in the results analysis. MD can offer more reliability than docking 
in predicting the conformational behaviour with time of a molecular system. However, it 
requires a greater amount of informatics resources, determining a longer computational 
time with respect to the simplest docking procedure. For this reason MD can be approached 
for lead optimization or, at maximum, at the hit selection step of the structure-based drug 
design workflow further described. 
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3.3. Quantum Mechanics (QM).  Quantum chemistry is that branch of physical chemistry 
that applies quantum mechanics and field theory to understand the electronic behaviour and 
the reactivity of atoms and molecules. With respect to MM, electrons are explicitly 
considered. Thus, atomic orbitals are described as electron clouds in which the relative 
probability to find electrons is about 90%. Molecular orbital calculations carried out 
accordingly, are even defined as electronic structure calculations and are based on solving 
the Schrödinger’s equation with the electronic molecular hamiltonian. 
For a molecule based approach, given a set of nuclear coordinates, all the other properties 
such as atom connectivity, point charges, polarizability and bond strength are directly 
calculated by the programs and do not need to be pre-assigned as in molecular mechanics. 
This level of theory implementation provides a higher reliability in predicting molecular 
properties and behaviour, even if the time for calculation remarkably rise up with respect to 
MM approaches. For this reason, by a quantum approach molecules or molecular systems 
constituted by less than 200 atoms can be studied, whereas, by MM approaches, the 
properties of systems constituted by thousands of atoms can be predicted. However, QM 
approach allows the study of not standard molecular properties and interactions related to 
the molecular electronic behaviour. For example, stacking interactions, chemical reactivity 
and electronic induction and transfer are not suitable for MM studies, but require a 
quantum methodology. 27,28 Finally, these properties have to be generally accounted for in 
the lead optimization phase, whereas they can be generally neglected in the initial 
screening phase of the SBDD workflow described below. The Gaussian03 program 29 was 
selected for molecular orbital calculations in our work. In the frame of the interaction 
between a target protein and a candidate drug, the QM approach has been applied for the 
fine prediction of electronic-related properties. In particular, desolvation contributions to 
the binding and π-stacking interactions were accounted for by quantum chemistry 
approaches. 
 
3.4.Integrated Approach. According to the molecular modelling overview presented above, 
the structure-based drug design approach carried out in this PhD work can be schematized 
as reported in Figure 2. The approach mainly used to simulate the interaction of small 
molecules towards target proteins is the docking calculation (dot line in Figure 2). This 
methodology, in fact, permits the analysis of thousands of molecules in a time much lower 
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than MD and QM based calculations; for this reason, docking simulation was used for 
preliminary virtual screening and rational drug design. In case of very large ligands, 
docking analysis was replaced by molecular dynamics calculations (see cap. 5.4). By the 
way, more sophisticated calculations were performed to optimize the most interesting hit 
and lead compounds. In particular, the necessity to explore the reciprocal protein-ligand 
adaptation and to analyze some fine molecular properties (especially those related to the 
electron transfer and polarization), has led to the introduction of two refinement cycles into 
the workflow. MD and QM were the preferred methodologies for these refinements, 
finalized to increase the success of the selected drug design approach. This general strategy 
has been adapted to the project carried out here and the predictions have been confirmed by 
the experimental results.  
 
 
 
Figure 2. SBDD workflow used in the presented work 
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4. Selected Target Proteins 
 
In this project, proteins belonging to three main families have been taken into account as 
drug targets. Here a description of the main features for each protein family and targeted 
ligands is provided. 
 
 
4.1. S100s  
S100 proteins are a highly conserved family of calcium-binding proteins found in 
vertebrates, and increasingly considered potential drug targets. 30-33 The name is 
hystorically derived from the fact that these proteins are 100% soluble in ammonium 
sulphate at neutral pH. More than 20 different members of the family are present in 
humans. S100 proteins are low-molecular weight protein dimers, Figure 3, where each 
monomer is constituted by an EF-hand domain, containing two helix-loop-helix motifs 
interconnected by a linker (hinge loop) and capable of binding two calcium ions in the 
loops, in a characteristic way.  
 
 
 
Figure 3. cartoon representation of a S100 protein (S100B). In blue and orange are 
evidenced the two monomer, in red spheres the calcium ions. The description of the helices 
is reported for only one monomer. 
 
The EF-hand domain in these proteins is characterized by the first loop being noncanonical 
(14 aa long) and by the first and last helices preceded and followed by residues with no 
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secondary structure. 34-36 Different S100 proteins are expressed in a tissue-specific and cell 
type-specific pattern. 37 In particular, their expression occurs in many different tissues 
including those of the nervous system, musculature, skin, adipose tissues, reproductive 
system, gastrointestinal system, respiratory system, and urinary system. 38-41 Importantly, 
these proteins regulate intracellular processes such as cell growth and mobility, cell cycle 
regulation, transcription, and differentiation. This suggests that different S100 proteins 
have different functions, and as they do not have any catalytic activity of their own it is 
likely that they regulate the activity of other proteins. Many of these regulatory pathways 
involve a direct interaction of a specific S100 protein with a particular target protein, so it 
is reasonable to expect that different members of the S100 family have quite different 
physiological roles. Misregulation of any of these interactions can thus cause pathologies, 
which makes S100 proteins potential drug targets. It is widely appreciated that inhibiting 
protein-protein interactions is a more ambitious goal than inhibiting, for examples, 
enzymes. 42 However, at variance with general enzyme inhibitors, S100 protein family 
members have a variety of partners and, therefore, ligand selectivity towards these proteins 
can be expected to be more easily achieved. 43 This family of proteins has been studied 
during the present project by following two different strategies. A first approach, based on 
molecular modelling procedures, was carried out in order to identify the S100B’s residues 
involved in substrate and ligand binding. In fact, only few ligands are reported to weakly 
interact with S100B, 44,45 and for these molecules structural detail of the interaction are not 
available. A second step was aimed at the in silico and NMR based identification of 
fragments able to interact with S100B and, separately, with S100A13.  
 
 
4.2.MMPs 
MMPs are a family of extracellular zinc and calcium dependent endopeptidases. 46 23 
members of the family plus a variable number of isoenzymes have been identified in the 
human genome and classified in 4 groups on the basis of their substrate specificity: i) 
Gelatinases (MMP-2 and MMP-9) are capable to digest type IV collagen and gelatin; they 
expose the gelatin binding region as a folding element close to the catalytic zinc binding 
motifs. ii) Collagenases (MMP-1, MMP-8, MMP-13) cleave collagen fibers at about ¼ of 
their length and are considered the only proteins able to degrade collagen fibers in 
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mammalian bones and cartilage. iii) Stromelysins (MMP-3, MMP-10, MMP-11) are not 
able to cleave collagen fibers but display a broad capability to cleave other extracellular 
matrix proteins. iv) mixed groups of MMPs that include elastase (MMP-12), matrilysin 
(MMP-7), enamelysin (MMP-20), membrane-type MMPs (MMP-14, MMP-15, MMP-16, 
MMP-17, MMP-24, MMP-25) and all the other members still not assigned to one of 
previously described groups. 47 From a structural point of view, all MMPs, with the only 
exception of MMP-7, are constituted by a catalytic domain connected to a haemopexin-like 
domain by a flexible linker (also called hinge region) that constitutes the recognition site 
for antibodies towards these proteins. MMP-2 and MMP-9 present an additional 
fibronectin-like domain.  
 
 
Figure 4. Cartoon representation of full length MMP-2, constituted by the catalytic domain 
(blue) that contains two zinc ions (magenta) and a variable number of calcium ions (cyan); 
the haemopexin domain (red) and the fibronectin like domain (green). The tertiary 
structure of gelatinase MMP-2 could be considered as representative for the entire family 
of MMPs, according to the specificity described in the text. 
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The haemopexin domain is reported to be fundamental for substrate recognition and, 
particularly, for collagen processing by presenting a single helix of collagen to the catalytic 
domain. Fibronectin-like domain presented by MMP-2 and MMP-9 participates in the 
interaction with gelatin substrate. 48 Moreover MMPs incorporate two zinc ions (one 
constitutive and one catalytic) in the catalytic domain, plus a numbers of calcium ions 
variable from one to three both in the catalytic and the haemopexin domain, as reported in 
Figure 4.  
These proteins are expressed in an inactive form on which a prodomain peptide is included 
in the structure to inhibit catalytic activity; the activation process is due to many different 
factors, including the mutual activation one, and is aimed at freeing the active site to the 
catalysis, by proteolytically cleaving the prodomain peptide. 49,50 Thus, MMPs are 
physiologically involved in degradation and remodeling of the ExtraCellular Matrix (ECM) 
components, cell movement, proliferation, and tissue expansion. In physiological 
conditions MMPs present a low expression profile and their activity is well regulated by 
TIMPs (Tissue Inhibitors of Metallo Proteinases), so that the ECM presents always the 
physiological organization and architecture. Due to an imbalance in the MMPs/TIMPs 
homeostatic system, often referred to an MMPs over-expression, the architecture of the 
ECM is altered, leading the tissue to a pathological condition that needs to be repaired. 51-54 
In some cases, the tissues themselves are able to repair the occurred damage, but when 
MMPs levels are too high or the damage is extended in time, tissues cannot recover. 
Accordingly, the application of synthetic MMPs Inhibitors (MMPIs) could represents a 
therapeutic opportunity for approaching all those disorders in which the restoration of the 
ECM organization is needed. In the last decades, many MMP inhibitors have been deeply 
investigated both in pre-clinical and clinical trials for their anticancer activity; however, 
none of them reached the market. In the last few years the interest for MMPs has resurged, 
and these proteins still represent a noticeable class of therapeutic targets. 
MMPs were extensively investigated during the present PhD project and constituted the 
core of the research activity carried out. Most part of the research in this field has been 
carried out in collaboration with ProtEra Srl, an Italian biotech company involved in drug 
discovery and focused on the development of MMPs inhibitors as therapeutic agents. In 
detail, two different approaches were carried out: a first and deep computational analysis 
for ligand design purposes, and a in vitro and in vivo evaluation of a MMP-9 inhibitor 
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therapeutic activity. In detail, a new scaffold for MMPs inhibition has been developed by 
the fine computational-based optimization of an already validated scaffold. The second 
approach was mainly focussed on the efficacy evaluation of MMPs inhibitors, previously 
studied by docking analysis, in the therapy of Dry Eye Syndrome. 55 In the field of MMP 
proteins a complete discovery activity was performed, starting from the early phases of the 
ligand selection (see workflow of Figure 2), until the preliminary analysis of the 
therapeutic activity and toxicity for the selected lead molecules.  
 
 
4.3. Tubulin and Microtubules.  
Microtubules are major components of the cytoskeleton of all eukaryotic cells. These 
polymers participate to the intracellular organization and maintenance of cellular integrity. 
They are essential for cellular life owing to their implication in numerous cellular 
processes, such as determination of cellular shape, position of organelles, cellular motility, 
movement of intracellular organelles and formation of the mitotic spindle during cell 
division. 56,57 Tubulin is a dimer of α/β subunits that consist of a core formed by ten β-
sheets surrounded by 12 α-helices. The most significant differences between subunits are 
situated in loop M (microtubule loop), which participates to lateral interaction between 
protofilaments. The most variable domains are located in the C-terminal of subunits that 
undergo post-translational modifications and are involved in protein-protein interactions. 
Due to structural and functional differences the α-subunit is always bound to GTP, whereas 
the β-subunit can also be loaded with GDP. Microtubules are cylindrical structures 
composed of α and β tubulin subunits, non-covalently bound together, that can assemble 
and disassemble in response to different cellular stimuli. The inherent microtubule 
dynamics is provided by hydrolysis of GTP and closely related with microtubule functions. 
Cellular microtubules appear as hollow cylinders of about 25 nm in diameter. The cylinders 
within cells are formed by the lateral association of 13 protofilaments on average. Each 
protofilament is a string-like structure, Figure 5, which consists of tubulin subunits that are 
arranged in a head-to-tail orientation, a property that confers a polarity to microtubules. 58 
The “head-to-tail” orientation of αβ-tubulin in microtubules results in a different subunit 
exposition at their ends: α-subunits are exposed to solvent at the minus end (-) and β- at the 
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plus end (+). Microtubule ends were named in this manner because “plus” end is more 
dynamic than “minus” end 
 
 
 
Figure 5. Schematic representation of microtubule organization. Microtubule polarity 
indicates that β-subunits are exposed at «plus» end, whereas α-subunits on «minus» end of 
the microtubule. 
 
These macromolecules have been targeted for cancer therapies aimed at stopping the 
mitotic division process of cancer cells. Numerous natural microtubule-targeting drugs 
were found in plants and animals that use these toxic molecules as passive defence. 
Nowadays, some of these drugs serve in medicine as effective anti-cancer agents that arrest 
the cell cycle and inhibit proliferation of cells. Microtubules become more dynamic when 
cells enter mitosis. The fundamental reasons of this phenomenon are still obscure; 
however, this higher dynamics is necessary for the formation of the mitotic spindle and 
proper chromosomal segregation. 59 The failure of mitotic spindle formation or its 
stabilization at the stage of chromosome segregation results in mitotic arrest. The most 
important drugs that act on spindle formation are colchicine, vinca alkaloids and paclitaxel 
(taxol). 60,61 It has been demonstrated that colchicine and vinca alkaloids bind alpha tubulin 
monomer in a pocket that is close to the interface of binding with beta tubulin. 61 The 
binding of these natural substances stabilizes a curved conformation of the tubulin 
heterodimer, Figure 6, which impedes longitudinal contacts in protofilament and leads to 
microtubule depolymerization. On the other hand it is accepted that taxol binds to β-tubulin 
on the inner surface of microtubule 62 and probably stabilize lateral contacts between 
protofilaments blocking mitosis even at concentrations several hundred times less than that 
of cellular tubulin. 
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Figure 6. Schematic representation for stabilization of curved heterodimer conformation by 
colchicines (shown as a black triangle). Modified from Ravelli et al., 2004. 61 
 
In addiction, many small proteins and peptides have been found to interfere with the 
tubulin polymerization process. Several of them belong to the stathmin family. It was 
discovered that the presence of stathmin destabilize microtubules, an effect first attributed 
to an increase of the transitions between growth and depolymerization phases 
(catastrophes). It was soon demonstrated that this effect also results from the sequestration 
of tubulin in a tertiary complex made of two tubulin heterodimers per stathmin molecule, 
reported in Figure 7. The stathmin molecule stabilizes a curved conformation of the pair of 
tubulin heterodimer in a similar way as observed for vinca alkaloids.  
 
Figure 7. X-Ray structure of the stathmin-tubulin complex (PDB entry 1SA0) at 3.58 Å 
resolution. In magenta stathmin, in green β-tubulin, in blue α-tubulin. Stathmin protein 
stabilizes the two heterodimer in a curved conformation. Moreover, a β-hairpine peptide of 
stathmin protein binds on α-tubulin, impeding the polimerization. 
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Moreover, it was observed that the amino-terminal end of stathmin binds to the α-tubulin 
subunit at the longitudinal interdimer interface. Both dimer curvature and steric hindrance 
of α-tubulin subunit by the N-terminal part of stathmin prevent incorporation of tubulin 
dimer inside the microtubule lattice. 63-66 Recent data show that stathmin strongly increases 
the catastrophe frequency at the minus ends due to direct interaction with pre-polymerized 
microtubules. 67 These data propose co-existence of two different mechanisms for 
regulation of microtubule dynamics by stathmin. 
These proteins were investigated during the development of an European Project (FP6, 
acronym: Nano4Drugs) aimed at the discovery and optimization of a drug delivery system 
for carrying protein-based anticancer drugs targeting tubulins and microtubules. Starting 
from an already known binding peptide derived from the amino terminal end of stathmin, 
computational tools were applied to identify the most promising mutations in terms of 
interaction energy towards alpha-tubulin and ligand stabilization. By the sequential 
application of homology modelling, molecular dynamics and free energy calculation by the 
solution of the Poisson-Boltzmann equation, we have selected new peptides theoretically 
able to bind alpha-tubulin with higher affinity with respect to the reference peptide. 
According to the aim of the project these peptide should constitute, in a first attempt, the 
protein-based drugs that have to be linked to a fluorescent nanodiamond in order to realize 
a traceable drug-delivery system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
5. Projects 
 
Here are described the projects carried out during this PhD training. For each project, a 
small introduction with rational for the development of ligands, a brief experimental 
session, the discussion of the results obtained and the description of the personal 
contribution are provided. 
 
5.1. Theoretical Study on S100B. 
This theoretical work has been aimed at the identification of S100B residues involved in 
ligand and substrate binding. This protein was selected within the S100 family due its clear 
involvement in human pathologies such as melanoma and neurodegenerative disorders. 68-73 
S100B is one of  the most promising S100 protein for drug designing purposes because it is 
reported to interact with the C-terminal negative regulatory domain of p53, a physiologic 
tumor suppressor protein that signals for cycle arrest and apoptosis. S100B is involved in 
the down-regulation of p53 and, as the inactivation of normal p53 functions is found in 
over half of human cancers, restoration of normal p53 functions through the destruction or 
prevention of S100B-p53 complex represents a possible approach for the development of 
new drugs. 74-76 Despite the potential application of S100B ligands, the limited availability 
of experimental information relative to S100B’s ligands binding conformation represents 
the main difficulty for drug design purposes. Only few ligands have been actually 
demonstrated to interact with S100B with micromolar affinity. 45 For these weakly binding 
molecules, experimentally determined structural information about the conformation of 
binding are not available. In this work, we have applied computational methodologies to 
available S100B-substrate complexes to provide information about the protein residues 
involved in ligand and substrate binding. Moreover, we have provided a docking based 
binding model for a organic compound, pentamidine, that is currently one of the few 
molecules reported to interfere with S100B-p53 adduct. 44 Molecular dynamics simulations 
77
 were carried out for the refinement of the three available structures of S100B bound to 
TRTK-12 and p53 peptides. 78-81 Solution structures of S100B complexes were retrieved 
from the Brookhaven Protein Database. Calcium loaded structures have been selected due 
the evidence that S100 proteins are activate by two calcium ions; the metal binding process 
provides conformational modifications that expose the hydrophobic binding core of the 
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protein towards the physiological environment, by increasing the angle between helices 3 
and 4 until about 85° (Figure 8). This mechanism of activation determines an increased 
affinity of S100 proteins towards their substrates.  
 
Figure 8. cylindrical representation of helices 3 and 4 of calcium loaded S100B (red) and 
helices 3’ and 4’ of apo  S100B (green). Helices 4 and 4’ of both structures have been 
manually over imposed, and vertically aligned in the figure in order to highlight the 
different orientation of the helix 3 and 3’. It is evident how the binding of calcium 
determines an angle θ between h3 and h4 of about 85 °, whereas h3’ and h4’ in the apo 
form are quite parallel (θ’) 
 
The computational analysis of side chain reciprocal movements in the selected complexes 
has revealed that only few residues play an important role in substrate stabilization and 
binding. In particular, F76 and V56 constitute a hydrophobic entrance to the substrate; 
moreover, F76 is involved in the stacking-based stabilization of aromatic side chains of 
these peptides. A further lipophilic interaction is mediated by a cluster of leucine and 
isoleucine residues distributed on helices 2 and 3 (L32, I36, L60). These residues’ side 
chains belong to the hydrophobic binding core of the S100B and correspond to the part of 
proteins that is exposed to the external environment during the calcium dependent 
activation. As a confirmation of the relationship between the 3D conformation of the 
protein and its binding affinity towards substrate peptides, the distance between c-alpha of 
F76 (h4) and V56 (h3) was measured. A distance comprised between 8.2 and 9.7 Å was 
found to be crucial for the interaction to occurs. All these information about the binding 
 27 
conformation of substrate peptides on S100B have been used to describe the putative 
binding pocket on which to target ligands.  
To complete the characterization of this binding pocket, the interaction between 
pentamidine and S100B has been studied in silico. Pentamidine is a member of aromatic 
diamidines, currently in widespread clinical use for the treatment of infections determined 
by Pneumocisti carinii Pneumonia. Isethionate salt, as approved by FDA, was 
experimentally observed to bind S100B at low micromolar concentrations. 45 With the aim 
to propose a computational-based binding model for this ligand on S100B, a molecular 
mechanics approach has been undertaken. The protein coordinates for the building of the 
potential grid map have been retrieved from the Protein Data Bank. The solution structure 
of calcium loaded human S100B in complex with TRTK-12 high affinity peptide (PDB 
1MQ1) 79,80 was selected because it describes the only available complex between human 
S100B protein and a substrate. After removing the coordinates of the binding peptide from 
the adduct, a short MD step has been applied to the backbone-restrained S100B protein in 
order to stabilize the new side chains conformation to their corresponding local minimum 
level. To describe the conformational accessibility of pentamidine on the binding core of 
S100B, two different simulations were performed. A first molecular dynamics approach 
has been carried out for the energy minimization (50K, 3ps) of the complex between 
S100B reference structure and pentamidine, manually placed in the above described 
binding pocket. In a second step, AutoDock program was applied for the automatic 
prediction of pentamidine binding conformation, and relative interaction energy. Due to the 
structural symmetry of this protein, both the simulations were performed in a single 
monomer. With those approaches, two main conformations of binding were identified. The 
interaction in the binding pocket has been predicted in the same way by AMBER and 
AutoDock, whereas some differences have been observed in binding the protein surface. 
However, the protein residues involved in pentamidine binding are the same observed to be 
involved in the interaction with substrates. According to these results, in the first surface 
conformation, predicted by AMBER package, a benzamidine group of pentamidine 
interacts with the N-terminal region of helix 3 close to the hinge loop. The main residues 
involved in this interaction are E51 (salt bridge) and V52 (hydrophobic interaction). In the 
conformation predicted by AutoDock the benzamidine group binds in the central region of 
helix 4. In that case V80 and A83 (hydrophobic interactions) were the mainly involved 
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residues, Figure 9. In conclusion, other than the above described residues involved in 
substrates binding, E51, V52, V56 and A83 seem to be crucial for ligands interaction on 
the surface of S100B, whereas F76 play a key role in the stacking stabilization of aromatic 
rings of both ligands and substrates. All these results have been used to describe a possible 
S100B binding pocket, Figure 10, providing the bases for a further drug design approach.  
 
 
Figure 9 – Binding conformation of pentamidine predicted by AMBER (left side) and 
AutoDock (right side). In green cartoon, sticks and lines is reported one monomer of 
S100B. In red spheres are highlighted the calcium ions. In violet is reported the second 
monomer of the S100B. The binding conformation of pentamidine was studied in only one 
monomer. It is observable that one of the two benzamidine group binds preferentially in a 
pocket described by F76, V56 and L60, whereas the other benzamidine group binds in the 
end of helix3 (amber) and in the end of helix 4 (AutoDock). 
 
 
Figure 10 – In stick: S100B residues involved in ligands and substrates binding 
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In this work I have contributed with the docking calculations of Pentamidine and with the 
molecular dynamics based analysis of the interaction between S100B and the high affinity 
peptides, available in the literature. Artur Gieldon has contributed with the Molecular 
Dynamics studies of the complexes between S100B and the peptides and between S100B 
and pentamidine. 
 
These results have been published in the Journal of Molecular Modelling 2007, 13, 1123-
1131 (Gieldon A., Mori M., Delconte R.) and the original publication is reported in the 
attachment (appendix) A. 
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5.1.1. NMR Study on Pentamidine Binding. 
Several attempts aimed to obtain the X-ray structure of the pentamidin in complex with 
S100B failed. Therefore, to obtain information on the binding mode of this micromolar 
ligand on S100B, the interaction with pentamidine was investigated following the chemical 
shift perturbations on 15N-1H HSQC spectra using 15N labeled protein samples. The 
chemical shift is a sensitive indicator of protein-ligand interactions and can be use to 
identify the binding site when the resonance assignment is available. 82,83 The complete 
assignment of the unbound form of S100B is available in our laboratory (results 
unpublished). Increasing amounts of pentamidine dissolved in DMSO (stock solution of 25 
mM) were added stepwise to 200 µM solutions of the protein up to a concentration of 1 
mM. Although several NH signals were shifted by adding the ligand, most of cross-peaks 
belonging to protein adducts with pentamidine, where easily re-assigned.  
 
 
 
Figure 11. 15N-HSQC spectrum of calcium loaded S100B (blue), calcium loaded S100B + 
pentamidine 0.2mM (green) and 1mM (red). In the box at the top-left is magnified the peak 
of V56, as example of a residue exhibiting strong chemical shift perturbations.  
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The binding site of pentamidine, was analyzed and compared by reporting the Garrett 
values [∆δ(NH)] on a cartoon and stick representation of the S100B structure (Figure 12).  
 
Figure 12 – S100B residues with significant 15N-HSQC chemical shift perturbations (CSPs). Red: 
residues exhibiting ∆δ>0.1 ppm; Blue: residues exhibiting 0.1>∆δ>0.04 ppm; green: calcium ions. 
 
As it is evident from Figure 12, the region with significant 15N-1H HSQC CPSs involves 
the protein region described by helices 3 and 4, with a particular involvement of the 
helices’ residues that constitute the above described hydrophobic binding core of S100B. 
The analysis of the Garrett values rules out relevant additive interactions of the 
pentamidine with different protein regions, suggesting two different binding mode as 
obtained by the MM calculations. The NMR-based data are in agreement with the 
theoretically predicted binding mode where the benzamidine group of pentamidine 
interacts with F76 (∆δ=0.04 ppm). At the same time the distribution of CSPs supports the 
MM calculations where the second benzamidine group switch between two different 
binding sites, one on helix 3 and the other on helix 4. However, the NMR data suggest a 
slightly different interaction between the ligand and the amino acids on helix 3, with 
respect to what predicted by the MM calculation, since only E46 instead of E51 
experiences a chemical shift alteration (∆δ=0.13 ppm).  
Interestingly, the predicted binding mode for pentamidine has been supported by some 
experimental data, confirming the possibility for this ligand to exploit the two predicted 
interaction with S100B (Figure 13). In conclusion, these results set the bases for the further 
drug design approach. 
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Figure 13 – Binding mode of pentamidine modelled on the basis of the 15N-HSQC chemical 
shift perturbations. A: pentamidine close to h3. B: pentamidine close to h4. In yellow stick 
pentamidine; in stick are highlighted the residues identified by 15N-HSQC experiments.  
 
The results of this NMR-based experiments are unpublished and were used to provide 
experimental confirmations to the previously described theoretical work on S100B. I 
contributed to this experimental investigation with the analysis of the HSQC spectra and 
the mean shift difference calculation. 
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5.2. Fragment Docking to S100 Proteins Reveals a Wide Diversity of Weak Interaction 
Sites. 
The results obtained by the theoretical approach to S100B and the experimental NMR-
based binding analysis for pentamidine provided useful information about the substrates 
and ligand binding mode of this protein. These results were exploited for a structure-based 
drug design approach aimed at the identification of new fragments and/or ligands able to 
bind S100B and S100A13. S100B has been taken into account as drug target for the 
reasons above described. On the other hand, S100A13 has been recently designated as a 
new marker for angiogenesis in human astrocytic glioma and as a regulator of the FGF-1 
release. S100A13 is widely expressed in various types of tissues, and shows a high 
expression level in thyroid gland. In smooth muscle cells, this protein is co-expressed with 
other family members in the nucleus and in stress fibers, suggesting diverse functions in 
signal transduction. 84  
In this work a combined NMR and docking-based approach was undertaken for the 
identification of the fragments binding sites on the surface of these proteins. This approach 
gave us the possibility to address some differences in ligand binding affinity and specificity 
between these two member of the S100 proteins family. Structure-based drug design and 
NMR-based screening were combined to identify the fragments binding sites on the surface 
of S100B and S100A13. To identify the binding sites we carried out an irrational approach 
based on the in vitro screening of a fragment library, whereas in silico tools were used for 
to predict the conformation of binding of most interesting hits. A fragment library of 430 
commercially available compounds was initially screened by NMR spectroscopy on each 
calcium loaded protein. This library does not completely agree with the Lipinski’s rules, 
85,86
 according to which a candidate drug molecule should adopt the following criteria: 
 
-Not more than 5 hydrogen bond donors 
-Not more than 10 hydrogen bond acceptors 
-A molecular weight under 500 daltons (from 160 to 480) 
-A partition coefficient logP less than 5 (in -0.4 to 5.6 range) 
-(number of heavy atoms from 20 to 70) 
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In bracket are reported some recently validated improvements to these rules. 87 However, 
this library of compounds with an intermediate molecular weight between fragments and 
ligands was selected to obtain preliminary binding information, because it was 
representative for the most chemical diversity as possible. 
A two step NMR approach was performed in the screening process. The ligand based 
WaterLOGSY 88 (Water Ligand Observed Gradient Spectroscopy) technique was applied 
for the initial screening in order to identify, for each protein, the set of promising hits 
showing a certain interaction with the protein. Water-LOGSY is a NMR-based experiment 
for the preliminary qualitative evaluation of the ligand binding capability towards a target 
protein. This technique is based on the magnetization transfer between irradiated water 
molecules and ligands, that are in the equilibrium state between the solvent and the protein 
bound form. By this experiment 56 and 47 fragments has been observed to interact with 
S100A13 and S100B respectively, and the most interesting evidence obtained by this 
preliminary approach is that the two proteins show a particular affinity towards the 
fragments. Only 13 fragments, in facts, bind both proteins. These two sets of fragments 
were then tested by 15N-HSQC experiments, with the aim to identify the relative protein 
residues involved in the binding of each fragment. The chemical shift perturbation (Garrett 
values) of uniformly 15N-labeled protein samples upon complex formation with ligands, 
provides a sensitive tool for the identification of binding sites. 82 The results analysis 
revealed that there are two main fragments binding regions on S100B, showed as cubes in 
Figure 14; the first (A) is located between the hinge loop and the C-terminal part of helix 4, 
and the second one (B) involves the hinge loop and helix 3. The hinge loop represents a 
bridge between these two areas, playing an important role in the interaction of ligands. 
Interestingly, these results are in good agreement with the in silico prediction of the S100B 
ligand binding area provided by the theoretical work described above, and by the NMR-
based study of pentamidine. 
 
 35 
 
Figure 14 – The two binding areas identified on the surface of S100B (black and grey 
cubes). Area A is located between the C-terminal of helx 4 and the hinge loop, whereas 
area B involves mainly the C–terminal of helix 3.  
 
On the other hand, three interaction areas have been found on S100A13, as reported in 
Figure 15; the first area (A) involves the second calcium binding site at the C-terminal part 
of helix 1, the second one (B) is located in the hinge loop region between helix 2 and helix 
3, including the C-terminal part of helix 4 and N-terminal part of helix 1, and the third area 
(C) is placed in the region of interaction of the monomers, mainly involving helix 4 and 
helix 1.  
 
Figure 15 – The tree interaction areas identified on the surface of S100A13 (in black, grey 
and light grey cubes). Area A is located in proximity to the second calcium binding site; 
area B includes the hinge loop between helix 2 and helix 3, whereas area C is placed in the 
region of interaction of the monomers. 
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By this first analysis these two protein displayed a different interaction path towards the 
same set of ligands, These results support the hypothesis of a selective ligands interaction 
between the family of S100 proteins. 
Despite the great contribution given by 15N-HSQC experiments in determining the protein 
residues involved in the fragments binding, and its fundamental application in mapping the 
above described binding areas, this method does not provides information about the 
conformation of binding for the tested ligands. Docking simulations have been performed 
for all those molecules that showed interaction in Water-LOGSY experiments, with the aim 
to understand the fragments conformation of binding in the areas identified by the NMR-
based screening. Protein structures identified by PDB entries 1YUU 89 and 1DT7 81 were 
selected for grid parameterization on S100A13 and S100B respectively. The grid maps 
calculations was performed on each NMR determined calcium loaded protein, selecting the 
structure with the lowest energy and the least restraint violations, and removing the 
eventually present binding peptides such as the C-terminal peptide of p53 protein. The 
entire surface of both the proteins has been considered during the docking calculations even 
if the grid maps were centered around a single monomer. The Lamarckian Genetic 
Algorithm (LGA) has been used for the automatic docking procedure and the global search 
method has been applied on each compound. Results clearly show that the fragment 
binding regions identified by the docking approach are consistent with the binding areas 
identified by 15N-HSQC experiments in both proteins. Moreover, each fragment binds 
preferentially in only one of the three areas identified for S100A13 and the two identified 
on S100B. The good quality of these results is even supported by the fine correlation of the 
predicted conformation of binding with the experimental HSQC data.  
The lead fragments providing the lower NMR-determined Kd values for the interaction to 
each protein were deeper analyzed. In particular, cromolyn (cromoglicic acid) 90,91 for 
S100A13 and alpha naphtol for S100B provided the better results in terms of binding 
energy and agreement of the docking prediction with experimental data. One of the 
possible parameters to evaluate the quality of a ligand is the ligand efficiency (LE), 92-95 
that is calculated as the ratio between Delta Energy of Binding towards the target protein 
and the ligand’s number of heavy atoms. Cromolyn is an antiallergic drug reported to 
interact with S100A13. To investigate the molecular bases of this interaction, a 15N-HSQC 
titration on S100A13 was performed and a Kd value between 100 µM and 500 µM was 
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obtained, providing a LE≈ 0.14. The strongest chemical shift perturbation due to the 
cromolyn binding was observed for residues within the binding site described by the 
interaction of the two monomer in correspondence of helix 4 and helix 1 (Area C in Figure 
8). These predicted data provide the structural bases for the interaction between cromolyn 
and S100A13 (Figure 16A). 
 
 
Figure 16 – A: binding conformation of cromolyn  on the binding area located at the 
S100A13 monomer interaction surface, between the two helices 4. B: binding conformation 
of alpha naphtol on the binding area close to the S100B’s hinge loop. 
 
Alpha naphtol (Figure 16B) is the strongest interacting fragment on S100B, providing a 
NMR determined Kd value between 50 µM and 200 µM and a LE≈ 0.5. To check the 
ability of this fragments in preventing the pathologically relevant interaction between 
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S100B and p53, the 15N labeled protein was titrated with this ligand in presence of a p53 
mimic peptide derived from the C-terminal regulatory domain of p53 protein (sequence 
SHLKSKKGQSTSRHKKLMFKTE). The titration was monitored by HSQC spectra, 
observing the effect on the S100B resonances upon the addition of the ligands. 15N labeled 
S100B was first titrated with p53 mimic peptide up to a 1:2 molar ratio with respect to the 
S100B monomer; then the alpha naphtol was added stepwise up to a molar ratio of 1:2 :4, 
respectively. By comparing the spectra it was observed that the addiction of alpha naphtol 
affects several peaks. Some of them are restored to the original position corresponding to 
the S100B-alpha naphtol complex; some other peaks were shifted to a new position that is 
different from that observed in S100B-p53 or S100B-alpha naphtol adducts (Figure 17).  
 
 
Figure 17 - Superimposition of two areas of 15N-HSQC spectra of 1) S100B + 5B adduct at 
1:2 ratio (red); 2) S100B+ p53 at 1:2 (blue); 3) S100B + p53 + 5B at 1:2 :2 (magenta); 4) 
S100B + p53 + 5B at 1:2 :4, (green). 
 
This points to alpha naphtol replacing a portion of the bound peptide molecule with a 
mixed competitive/noncompetitive behaviour. The other portion of the p53 mimic peptide 
presumably rearranges in a new conformation to avoid conflict with the surface portion 
occupied by the fragment. The peaks that are restored clearly identify the region of the 
protein where alpha naphtol binds, in good agreement with the previously described 
binding areas. 
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In conclusion, the combination of in silico prediction and NMR experiments provided the 
structural bases for the identification of two binding areas on the surface of S100B, and 
three binding areas on S100A13. Although the two proteins have quite similar quaternary 
structure and a common binding area (around the hinge loop), our results showed that they 
have only a few ligands in common, suggesting that selective ligand could be developed 
starting from the different lead fragments with high LE values, identified herein. Coupling 
of the experimental data with docking results indicated the most probable docked 
conformations of the ligands on the proteins surface. The study on the antiallergic drug 
cromolyn provided for the first time structural information for the interaction, and 
demonstrated that cromolyn has a unique binding site on the protein surface. Finally, 
competition experiments conducted with a-naphtol on the S100B–p53 peptide complex 
showed that even if the ligands identified by the NMR screening bind weakly on the 
protein surface, they are able to significantly interfere with the interaction with other 
proteins or peptides. 
These results constitute a good starting point for the in silico and experimental 
development of new ligands that could play an important role in the protection of p53 from 
S100B-dependent down regulation. S100 proteins in general are becoming targets of 
pharmaceutical interest because of their involvement in cellular functions. The present data 
suggest that selective and high efficacy modulators of their activity are within reach of 
current lead development strategies. 
 
In this work I have done all docking calculations on both S100 proteins and all necessary 
parameterizations related to the docking procedure. 
 
These results have been published on ChemMedChem journal, 2007, 2, 1648-1654 (Arendt 
Y., Bhaumik A., Delconte R., Luchinat C., Mori M., Porcu M.). The original publication is 
reported in Appendix B  
 
 
 
 
 
 40 
5.3. Computational Approach to the Optimization of The Classic Aryl-Sulphonamide 
Scaffold for MMPs Inhibition. 
Many proteins such as MMPs have been structurally characterized in complex with 
synthetic molecules and substrates. In these cases the ligand conformation of binding can 
be exploited for the design of new focussed molecules approaching a structure and ligand-
based drug design strategy. As above described, the availability of the 3D structures of 
target proteins in their complex conformation represents a great advantage for drug design. 
However, not always these ligands perform the most of the favourable interactions with the 
protein, and a lack of ligand optimization can be observed. In these cases, a refined in silico 
approach can be undertaken with the aim to improve the ligands efficacy. In this work we 
have applied computational tools to refine and optimize a validated scaffold for MMP 
inhibitors. 
MMPs are a family of proteins considered as pharmaceutical targets due to their 
involvement in various human diseases. Other than cancer, MMPs are involved in many 
different pathologies such as periodontitis, dry eye syndrome, skin aging and inflammation 
that could be managed in a topical way, especially in the attempt to avoid all the side 
effects observed during the systemic administration of MMPs inhibitors and related to their 
lack of selectivity. 96 In this field, the development of strong MMPs inhibitors is still 
representing a possible therapeutic opportunity. Many experimental structures of MMPs are 
available and most of them describe their complex with synthetic inhibitors. A fine analysis 
of these 3D structures, however, reveals that most of these molecules lacks of optimization 
towards their target protein. In particular, for the molecules belonging to the most 
speculated hydroxamic aryl sulphonamide scaffold, small structural changes could be 
hypothesized in order to increase their binding affinity.  
During this phase of the PhD project, computational tools have been applied for the 
optimization and refinement of hits. According to the workflow described in Figure 2, this 
strategy properly corresponds to a structure and ligand-based drug design approach 
finalized to the lead discovery and optimization. The work started with the analysis of the 
available PDB structures that describe the complexes between MMPs and hydroxamic aryl 
sulphonamide inhibitors. 97-100 The 3D conformational analysis at atomic level of detail 
revealed two main portion of the reference scaffold on which to focus some chemical 
modifications. All these molecules, in fact, did not perform a geometrically correct stacking 
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interaction with a highly conserved aromatic residues of MMPs (zinc-binding histidine); 
hence, a linker between the sulphonamide moiety and the so called P1’ aromatic portion 
can be introduced in order to better perform this interaction. Moreover, the amino acidic 
block of the reference scaffold can be modified by introducing an additional carbon chain, 
with the aim to decrease the solvation energy of free inhibitors. From a thermodynamic 
point of view, during the ligand protein interaction process many variable can play a key 
role in determining the ligand’s affinity. One of this is exactly the solvation/desolvation 
effect by which a lower ligand solvation energy provides lower free energy of binding, with 
respect to more water solvated ligands. 101-103 Therefore an improving in ligands efficiency 
can be achieved by playing with water solvation/desolvation effects. Thus, the amino acid 
residue of the reference scaffold has been modified by substituting the classic glycine with 
a D-proline; in addiction, a carbon linker was inserted between the sulphonamide group 
and the so called P1’ aromatic portion of inhibitors. D-proline was selected for its cyclic 
restrained features in order to avoid any possible energy indetermination related to the side 
chain’s fluctuation of non cyclic residues. On the other hand, the dimension of the linker 
has been chosen to maintain the binding conformation as much similar as possible to the 
reference scaffold, keeping the P1’ aromatic portion inside the so called S1’ lipophilic 
pocket characteristic of MMP proteins. By a comparative docking analysis of molecules 
equipped with one, two and three carbon linker, the two carbon based was selected for 
further investigations. By the combination of these modifications, an initial small library of 
12 compounds was generated. Docking procedures were applied to this library in order to 
estimate the effective advantage in MMPs binding with respect to the compounds 
belonging to the classic scaffold. These preliminary docking calculations were performed 
towards MMP-12 in order to have a direct comparison with the further presented in vitro 
and crystallographic data, easily available for this protein. Moreover, the modifications to 
the scaffold affect the protein binding in some particular region on which MMPs display a 
high sequence and structure homology; 104 for this reason MMP-12 can be considered as 
representative for the entire family of proteins. The docking results showed that there is an 
advantage in free energy of binding due to the D-proline based introduction, whereas the 
linker effect seems to be not equally performing. Crystallographic data and fluorimetric 
assays provided experimental confirmations of the predicted binding pose and relative 
affinity trend towards MMP-12. In particular, these results showed that the linker is able to 
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push the fist aromatic ring more deep inside the S1’ pocket, positioning the ring itself in a 
parallel displaced conformation for stacking interaction towards the aromatic imidazole 
ring of the highly conserved zinc binding histidine of MMPs (Figure 18). 
 
 
Figure 18 – Overlap of the binding conformation of a classic (cyan) and a optimized 
(green) inhibitor. In grey stick is highlighted the aromatic side chain of Zinc binding 
histidine (His113). 
 
It is known that this conformation provides lower interaction energy than the sandwich like 
conformation displayed by the classic scaffold. 105,106 Moreover, fluorimetric assays have 
pointed out the higher inhibitory activity of molecules bearing the linker with respect to the 
classic ligands. The fine analysis of the single atom energy contribution to the enthalpy of 
interaction, carried out by docking refinement of the X-Ray structures, was not able, 
however, to pick out the molecular determinants responsible for the observed binding 
improvement. The same limit has been observed during the automated docking-based 
energy calculation. Therefore a more sophisticated analysis was required due to the limits 
of molecular mechanics in correctly parameterise these systems. The most reliable 
approach to predict both solvation effect and, in particular, stacking interaction energy is 
represented by the quantum mechanics. Ab initio second order Møller Plesset perturbation 
theory (MP2) and SCRF-PCM methods were applied to calculate the π-π interaction energy 
and the solvation energy of each isolated compounds respectively. 106-108 Self-Consistent 
Reaction Field methods were exploited to calculate the energy of a system in solution (in 
this case a water solution), applying the Polarizable Continuum Model in which the cavity 
where the solute is placed is created via a series of overlapping spheres of solvent within 
the reaction field. MP2 method was selected for a more accuracy calculation of the 
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interaction energy than simple Hartree-Fock theory, due to the introduction of the 
electronic perturbation of molecular orbitlas. The results of solvation energy calculations 
carried out with SCRF(PCM) methods at the Hartree-Fock level of theory with a 
moderately large basis set (6-311++G(d,p)), clearly show that the D-proline residue 
determines a massive decrease of the ligand solvation energy with respect to glycine. On 
the other hand, the linker introduction does not determines the same effect, providing 
higher values for solvation energy that are included within the standard error for the 
selected method (see Table 1 and 2). 107 
 
 
 
Table 1 – Solvation Energy differences between classic and new molecules, calculated with 
Gaussian (PCM method). ∆∆Gsolv values are significant for the different energy 
contribution provided by glycine (left column) and D-proline (right column). 
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Table 2 – Solvation Energy differences between glycine-based and proline-based 
molecules, calculated with Gaussian (PCM method). ∆∆Gsolv values are not significant and 
included within the standard error of the method. 
 
This evidence, however, set the bases for the further QM approach aimed at the calculation 
of stacking interaction energies for the aromatic systems in protein/inhibitors adducts. In 
fact, the PCM calculations evidenced that the experimentally observed positive effect of the 
linker to the binding can not be attribute to the solvation/desolvation effect. The main 
conformational difference between classic and the new scaffold can be found in the S1’ 
pocket. In particular, the X-Ray determined different position of the inhibitor’s P1’ 
aromatic ring towards the imidazole side chain of the zinc binding histidine reflects, as 
already assumed, a different conformation for π-stacking interaction. To evaluate the 
energetic contribution of these two stacking conformations, MP2 interaction energy 
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calculations were performed applying a moderately large basis set (6-311++G(d,p)) on 
coordinate’s systems isolated from the correspondent X-Ray structures. These calculations 
were performed on the lowest molecular weight compound of each scaffold. The studied 
systems were constituted by the catalytic Zn(II) ion, the three imidazole rings of zinc 
binding histidines (on which the Cβ have been transformed into methyl groups), and the 
inhibitor, as reported in Figure 19.  
 
  
Figure 19 – The two systems extrapolated from X-Ray determined adducts of classic (left) and 
optimized  inhibitors (right). 
 
Interaction energy between Zn-his(3) and inhibitor was calculated as the difference 
between the total energy of the system and the sum of the energy of each component. BSSE 
was corrected during the calculations at the counterpoise level. 109 The results clearly show 
that the linker introduction determines an effective decrease of the interaction energy, with 
respect to the classic scaffold. From the evidence that the only difference in those systems 
is represented by the reciprocal position of the two aromatic rings in performing π-π 
interaction, this energetic difference can be attributed to the different stacking 
conformation. Thus, as above assumed, different conformations for π-π interaction 
correspond to different interaction energy. The energy values calculated with this approach 
reflect the higher stability of the parallel displaced reciprocal position of the aromatic rings, 
with respect to the sandwich like conformation observed for classic scaffold. This approach 
has been applied for the optimization of the interaction between ligands and MMP-12, but 
can easily be extended to other MMPs due the high sequence and structural conservation of 
the protein residues involved in the binding of these ligands. 104 In conclusion, both linker 
introduction and D-proline substitution at the same time in the hydroxamic aryl 
sulphonamide scaffold for MMPs inhibitors provide higher affinity towards these target 
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proteins. The computational approach here investigated was able to identify the ligand’s 
molecular determinants responsible for the observed binding improvement.  
 
This computational work on MMP proteins was mainly carried out by me. 
 
These results are going to be submitted for publication, and the draft is reported in 
appendix C 
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5.4. Design and Virtual Screening of a Focussed Library of Peptides Towards alpha 
Tubulin. 
In the frame of an European project (FP6, acronym: Nano4Drugs), in silico methodologies 
have been applied for the discovery of new tubulin binding peptides as candidate protein-
based drugs. According to the overview described above (see chapter 4.3), the dynamics of 
tubulins and microtubules is affected by molecules, such as natural alkaloids or stathmin 
protein, that interact with alpha tubulin stabilizing a curved conformation of the 
heterodimer constituted by α and β tubulin. This particular conformation impedes the 
polymerization of tubulins into microtubules, and determines cellular apoptosis. Thus, the 
development of molecules able to interfere with the dynamics of tubulins and microtubules 
could represent a new therapeutic approach towards cancer.  
Using available structures of tubulin, microtubules and microtubule associated proteins, we 
have applied a preliminary docking based virtual screening of the “NCI-DIVERSITY Set” 
(about 2000 compounds representing the broader chemical space of the 140,000 or so 
compounds in its holdings) to define and characterise the individual molecular targets 
present in these proteins. 110 The resulting data allowed us to optimize protein-based drug 
candidates in terms of selectivity and potency through the analysis of structure and 
energetic aspects of binding. One of the putative binding areas correspond to the region of 
interaction of a small peptide (19aa) derived from stathmin. This peptide, also called I19L, 
has been demonstrated to interfere with the tubulins polymerization and dynamics; for that 
reason it constituted the reference scaffold for the generation of the initial focused virtual 
library of peptides by applying single point mutations and double consecutive-point 
mutations. 
The initial library was screened by in silico procedures. In particular, a first homology 
modelling step on the reference 3D structure of alpha tubulin bound to the I19L peptide 
(unpublished data) was carried out. The 2D sequences of single point mutants and double 
consecutive point mutants were modelled on the 3D structure of I19L, in its complex 
conformation, until their state of energy minimum; the corresponding 3D adducts with 
alpha tubulin were then refined by a short molecular dynamics step. At the end of the MD 
calculations the peptide energy and the delta energy of binding between each peptide and 
tubulin were calculated by solving the Poisson Boltzmann equation. 111 Internal Energy and 
∆ Energy values were taken into account for the scoring analysis on the mutants, as 
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described in Table 3. Internal Energy describes the peptide energy in the binding 
conformation, whereas ∆ Energy correspond to the interaction energy between peptides and 
tubulin, and is calculated by solving the Poisson-Boltzmann equation towards these 
systems. 
 
 
Table 3 – Best results obtained by the single and double point mutation of I19L peptide. In 
red are highlighted the peptides tested in vitro. Internal Energy is the total energy of each 
peptide in the complex conformation and ∆ energy is the free energy of interaction between 
each peptide and alpha tubulin. All values are expressed in Kcal mol-1 and have been 
extrapolated from the molecular dynamics output file by solving the Poisson-Boltzmann 
equation. 
 
The most promising hits come out from this preliminary analysis were proposed for in vitro 
testing. Efficacy of these new hit peptides was quantified by their effects on microtubule 
mass and dynamics in vitro. The most efficient mutant was the peptide called K4R that was 
selected for a further in silico refinement cycle on which it was subjected to single point 
sequence mutations, homology modelling and MD energy minimization, as previously 
described. The final Energy calculation step pointed out the large interaction energy 
improvement due to substitutions in positions 10, 14 and 19 of the beta-hairpine peptide 
scaffold. Moreover, the ligand energy was surprisingly decreased in the cases of arginine 
substitution applied in the previously mentioned positions.  
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Tables 4 and 5 – Best results sorted by Delta Energy of binding (upper table) and Ligand 
Energy (down table), as obtained from K4R refinement cycle. These energetic values have 
been calculated in the way as above described. 
 
The conformational analysis of the in silico predicted complexes between alpha tubulin and 
peptides of tables 4 and 5 revealed that arginine enriched peptides are able to interact with 
a cluster of -1 charged residues that are present in the binding pocket of tubulin. In 
particular, the position 10, 14 and 19 are the most suitable for arginine substitution due to 
their close proximity and correct directionality with respect to glutamate and aspartate 
residues of tubulin.  
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Figure 20 – Conformational details of arginine enriched peptides in complex with α 
tubulin. 
 
The linear combination of these mutation represented the final step of the peptides 
optimization process. The above described protocol was applied to the mutants reported in 
the table below. As observable, both the energetic parameters remarkably decrease.  
 
 
Table 6 – Energy results obtained from the combination of the favourable single point 
substitution to K4R peptide. Results are expressed in Kcal mol-1, and have been calculated 
as above described. 
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The conformational analysis also revealed that all arginine substitutions are functional for 
targeting aspartate and glutamate residues placed in the selected binding region of alpha 
tubulin. The histidine substitution performed in position 14 is not able to provide low 
energy values as observed in case of arginine substitution; thus, arginine-based peptides 
have been proposed for a in vitro test that is currently under development from one member 
of the Nano4Drugs consortium. Despite the increased binding affinity and ligand 
stabilization, these peptides display a higher values for theoretical Isoelectric Point due to 
the increased total charge. This effect could negatively affects the cell membranes 
penetration of the drug peptide. Nevertheless, it has been reported that arginine enriched 
peptides are generally more active than others to cross the biological membranes. 112-114 
A10R_A14R and A10R_AA14R_L19R mutants have been proposed, together with the set 
of tables 4 and 5, as the lead peptides for the final in vitro and in vivo efficacy evaluation. 
In case that in silico predictions will be experimentally confirmed, these peptides would 
probably represent the protein-based candidate drugs aimed at stabilize/destabilize 
microtubules, according to the consortium achievements. 
 
I have contributed to this work with most of calculations on the initial library, focussed on 
I19L peptide, and with all calculations on the second library focussed on K4R peptide, until 
the selection on the lead peptides. 
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5.5. In Vivo Efficacy Evaluation of a MMP-9 inhibitor in Dry Eye Syndrome. 
Computational methods are generally employed in drug discovery pipelines. Despite their 
precision and accuracy in predicting molecular behaviour, the results obtained by these 
approaches need to be experimentally confirmed. In this way in vitro and in vivo 
experiments are aimed at providing more precise information about the efficacy, toxicity 
and bioavailability of the selected lead molecules.  
In this part of the project we have preliminarily in vitro and in vivo evaluated the 
preclinical efficacy and safety of a MMP-9 inhibitor, called PES_103, in the therapy of Dry 
Eye Syndrome (DES). 115 MMP-9 is a member of gelatinases group and is involved in 
many different human diseases such as cancer and systemic syndromes. 116 To evaluate the 
efficacy of a synthetic inhibitor selected by computational and in vitro approaches, 
experimental studies have been performed. In particular, the inhibitory activity of this 
molecule in the therapy of Dry Eye Syndrome (DES) was evaluated.  
Dry Eye Syndrome or Keratoconjunctivitis sicca (KCS) is an eye disease caused by the 
chronic lack of lubrication and moisture in the eye. In humans it can be caused by a 
decrease in tears production or an increase in tear film evaporation. Both eyes are in 
general affected and the physical damages occurs mainly at the corneal level. 117 Causes of 
this syndrome may be attributed to many different factors and, according to a recent 
statistic, more than 20 million Americans may be suffering from Dry Eye. 118 The 75% of 
the population over the age of sixty-five years is affected by this syndrome that is currently 
managed by the topical administration of artificial tears (AT). This symptomatic approach 
is right now the most efficient commercially available management for dry eye but it 
requires frequent application, without providing long term efficacy.  
One of the pathological consequences of eye dryness is reported to be the over-expression 
of MMP-9 (Collagenases B) at corneal level. This protein is a marker of eye dryness; 
nevertheless it has been demonstrated that knock-out mice for the gene coding for MMP-9 
protein are not able to develop experimental dry eye, leading to the evidence that this 
protein is somehow involved in the dryness process itself. 115 Accordingly, a possible 
asymptomatic therapeutic approach to DES could be represented by the eye topical 
administration of a MMPs inhibitor with a particular affinity towards MMP-9. The aim of 
the presented investigation was the preclinical evaluation of an in house developed MMPs 
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inhibitor, coded as PES_103, in the treatment of dry eye. This molecules has a high affinity 
towards the target protein (Ki=14 nM) and a high water solubility (more than 40 mg/ml).  
This experimental work started with a in vitro analysis of the inhibitory activity of the 
selected inhibitor. HT1080 are sarcoma cells with a high secretion of MMP-2 and MMP-9. 
119
 HT1080 conditioned medium was then analyzed by gelatine zymography in presence of 
increasing concentrations of PES_103. The gelatin zymogram of HT1080 culture 
supernatant is presented in Figure 21. Untreated supernatant (left hand column) produces 
tree bands of molecular weights 92 kDa, 82 kDa and 72 kDa representing pro-MMP-9, 
active MMP-9 and fused band for MMP-2 that include both the pro-domain and active 
forms, respectively. The incubation of 150 µl medium for 24h together with increasing 
concentrations of PES_103 (1, 3, 25, 50 and 75 mM) provided a decreased intensity of the 
band associated to active MMP-9, as a probable consequence of PES_103 inhibitory 
activity. 
 
HT1080 1 3 25 7550
92 KDa
82 KDa
72 KDa
mM
MMP-9
MMP-2
 
 
Figure 21. Gelatin zymogram of equal volumes of medium conditioned by HT1080 cells; 
The numbers give millimolar (mM) concentration of PES_103 added in the culture. 
 
Once achieved the in vitro confirmation of the inhibitory activity of PES_103 towards 
MMP-9, the biggest challenge was the demonstration of the MMP-9 involvement in the 
dryness process, and then the evaluation of the efficacy of PES_103 on the adopted animal 
model for DES. To evaluate the over-expression of MMP-9 in association with eye 
dryness, Experimental Dry Eye (EDE) was induced in C57BL/6 mice by transdermal 
application of scopolamine patch. As described by Dursun et al. 120 scopolamine resulted in 
a significant decrease in tears production due to the cholinergic-based blockade of the tear 
gland’s muscles. The effective dryness was verified by measuring the tears production with 
phenol red–impregnated cotton threads, while the active MMP-9 over-production was 
checked by gelatine zymography after tears collection. As reported in Figure 22, the ocular 
dryness condition occurs after about 24 hours from the transdermal scopolamine 
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administration. Tears volumes remain at low levels (dry eye) until about 60 hours; after this 
time they quickly recover until the physiological level (black histograms; control mice). On 
the other hand, zymographyc plots clearly show that high levels of active MMP-9 in tears 
fluid are observable starting from 24h until 48h from the SCP administration. 
 
 
standard 16h 24h 32h 40h 48h 54h 72h
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 Figure 22 – Plot of the tear production (top) and active MMP-9 expression levels (down) 
 
In conclusion, the most important feature merged from this experiment is the relationship 
between MMP-9 over-expression and dry eye induction that allows the possibility to 
evaluate the efficacy of the selected inhibitor in the asymptomatic treatment of dry eye. 
Before to proceed with the efficacy test, the safety of PES_103 was tested. Toxicity was 
preliminarily checked by in vivo and histological assays on treated and control mice. 
PES_103 was applied in sterile physiological buffer solution at 0.01%, 0.1% and 1% 
concentrations. Fluoresceine plus UV light and lissamine green were applied on the mice’s 
eyes to verify the complete absence of corneal ulceration and keratinisation processes, 
respectively. 121,122 Histological analysis of eye sections after H&E and Tunel colouring 
treatments revealed the absence of tissue alteration or increased number of apoptotic cells 
with respect to the control, untreated, mice. The lack of toxicity on mice was considered as 
a milestone step before to proceed with the efficacy evaluation. 
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The final part of this work was aimed at the evaluation of the efficacy of the selected 
molecule on the validated animal model. Scopolamine patches were applied on the mice’s 
midtail in order to produce eye dryness. Then, EDE mice were treated for 5 days, twice a 
day, with PES_103 0.1% (3 mM). This specific concentration of MMPs inhibitor was 
selected by a dose finding study on which the above described concentrations were 
preliminarily tested on the selected animal model (data not presented). The efficacy of the 
selected MMP-9 inhibitor was finally evaluated by the comparison of the tears volume of 
PES_103 treated EDE mice with respect to the same variable measured in control, only 
EDE, and AT treated EDE mice. Tear volumes were measured immediately before and 
after 30’ and 60’ of each administration. The plot of the tears volume for each group, 
Figure 23, clearly evidences the higher efficacy of PES_103 in restoring the tears 
production (60%), with respect to EDE mice (25%) and AT treated EDE mice (40%).  
 
 
Figure 23 – plotting of the tear volume (percentage with respect to control mice) over the 
time of the four measurements session. MMP.9 levels are detectable from the beginning of 
the first session until the end of the second, as reported by the red line. 
 
Interestingly, the effects of PES_103 seems to be related to the corneal level of MMP-9 
whereas AT, for example, display always a constant profile. When the MMP-9 level are no 
more detectable by zymography (beginning of the third session in Figure 23), the efficacy 
of PES_103 is quite similar to those observed for artificial tears. This PES_103’s behaviour 
could account for an asymptomatic mechanism of action. 
In conclusion, in this work we have verified that inhibiting MMP-9 at corneal level could 
represent a therapeutic opportunity to manage Dry Eye Syndrome. Moreover, we provided 
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support to the asymptomatic and therapeutic mechanism of action of PES_103, evidencing 
that its potency in restoring the tears production is proportional to the corneal MMP-9 
levels. Finally, we have been able to verify the good quality of the in silico prediction for 
the tested molecules towards MMP proteins.  
 
I have physically participated to the in vivo tests of the MMP-9 inhibitor, and I have 
essentially planned and contributed to execute the necessary experiments for toxicity and 
efficacy evaluation of the selected molecule. 
 
These results are going to be submitted for publication, and a early draft is included in 
appendix D. 
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6. Conclusions 
 
In this work are presented the results obtained in carrying out projects in the frame of 
structure-based drug design. Computer aided methodologies were applied to simulate the 
biological behaviour and physical/chemical properties of ligands during the protein binding 
process. In detail, ligands belonging to the classes of enzyme inhibitors, protein signalling 
pathway modulators, and protein-protein interaction inhibitors were analysed. 
Computational tools were applied to simulate the interaction between ligands and the 
potential pharmacological target proteins, chosen on the basis of their involvements in 
human diseases. Molecular mechanics methodologies were applied for ligand virtual 
screening and preliminary docking simulations of the interaction between ligands and the 
selected target protein; molecular dynamics was also applied in the hits refinement step, 
with the aim to simulate the reciprocal adaptation of protein and ligands during the 
interaction. Quantum mechanics methods were finally used for the fine analysis of electron 
correlated ligands properties, such as solvation/desolvation effects and π-stacking energy 
calculations. All those procedures were applied in a drug discovery pipeline with the aim to 
identify the set of promising hit or lead compounds on which to concentrate the in vitro and 
in vivo analysis. 
Finally, an in vivo experimental session was carried out to evaluate the quality of the in 
silico prediction. More precisely, the preliminary therapeutic activity of a MMP-9 inhibitor 
was succesfully verified in an animal model of Dry Eye Syndrome, confirming the 
capability of the applied computational protocol in predicting the biological behaviour of 
this class of molecules. The results herein presented highlight the advantages and the 
worsening of applying in silico structure-based drug design approach in a drug discovery 
pipeline. 
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Original Paper 
Theoretical study on binding of S100B protein  
Artur Gieldon1, 2 , Mattia Mori1 and Rebecca Del Conte1 
(1)  Protera S. r. l., Viale delle Idee, 22, 50019 Sesto Fiorentino (Fi), Italy 
(2)  Institute of Biochemistry, Johan Wolfgang Goethe University, Max-von-Laue-Str. 7, 
60438 Frankfurt a.M., Germany 
Received: 27 March 2007  Accepted: 29 June 2007  Published online: 23 August 2007  
Abstract  S100B protein is one of the factors involved in the down-regulation of tumor 
suppressor protein p53, a transcription activator that signals for cycle arrest and 
apoptosis. As the inactivation of normal p53 functions is found in over half of human 
cancers, restoration of normal p53 functions through the destruction or prevention of 
S100B - p53 complexes represents a possible approach for the development of anti-cancer 
drugs. The aim of this work was to propose the S100B binding interface through an 
examination of the literature and use of molecular modeling (MM) techniques with 
AutoDock program and the AMBER force field. We propose two residues in the S100B 
binding pocket (Val56, Phe76) and two residues on the protein surface (Val52, Ala83) are 
essential for ligand binding. The data presented here indicate that interactions with these 
four residues are necessary for a reduction in the incidence of the S100B - p53 complex. 
Additionally, we have tried to explain a mechanism for the action of pentamidine, the 
best-known S100B ligand, and have proposed two S100B - pentamidine structures. The 
results presented here may be useful for the efficient design of new S100B ligands.  
Keywords  AMBER - AutoDock - Pentamidine - p53 - S100B - TRTK-12  
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Fragment Docking to S100 Proteins Reveals a Wide Diversity of Weak Interaction Sites (p 1648-1654) 
Yvonne Arendt, Anusarka Bhaumik, Rebecca Del Conte, Claudio Luchinat, Mattia Mori, Marco Porcu 
Published Online: Aug 20 2007 1:52AM 
DOI: 10.1002/cmdc.200700096 
  
NMR screening of two S100 
proteins which are potential drug 
targets has been performed with a 
fragment library. A relatively large 
variety of interaction regions for 
various ligands for the two S100 
proteins were identified even 
applying computer-aided drug 
design. Our results show that they 
have only few ligands in common, 
suggesting that selective leads 
could be developed starting from 
the different hits identified in the 
present work. 
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“Computational approach to the optimization of the 
classic aryl-sulphonamide scaffold for MMPs inhibition” 
(Tentative Title) 
 
 
 
 
 
 
 
Abstract 
In this work we present a new computational approach to the design of new potent inhibitors of 
matrixmetalloproteinases (MMPs) by optimizing validated scaffolds. Starting from the analysis of 
X-Ray adducts of MMP-12 with classic aryl-sulphonamide inhibitors, computational tools have 
been applied in order to estimate the advantage in binding affinity, determined by two selected 
modifications: i) linkage of the sulphonamide group and P1’ aromatic ring with a carbon linker and 
ii) D-proline substitution instead of glycine residue in the amino acid portion. Theoretical results 
have been experimentally confirmed by fluorimetric assays and X-Ray crystallography. Since the 
intermolecular interaction energy calculated by a standard docking program didn’t provide accurate 
explanations for the observed binding improvements, ab initio PCM and MP2 calculations have 
been carried out to evaluate: i) the proline desolvation contribution, and ii) the contribution of π-
stacking interactions between the inhibitors and aromatic residues in the MMPs active site. Here we 
demonstrate that the introduction of the linker and D-proline residues at the same time in the 
reference scaffold, generates ligands with improved potency.  
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